News Hikma buys potential Epipen rival from troubled Insys UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi
Sales & Marketing Q4 results roundup 2019 With the full year results season drawing to a close, Richard Staines asks who the winners were and who has been left playing catch-up.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
